Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Michael Bristow to Animals

This is a "connection" page, showing publications Michael Bristow has written about Animals.

 
Connection Strength
 
 
 
0.488
 
  1. Tatman PD, Kao DP, Chatfield KC, Carroll IA, Wagner JA, Jonas ER, Sucharov CC, Port JD, Lowes BD, Minobe WA, Huebler SP, Karimpour-Fard A, Rodriguez EM, Liggett SB, Bristow MR. An extensive ?1-adrenergic receptor gene signaling network regulates molecular remodeling in dilated cardiomyopathies. JCI Insight. 2023 08 22; 8(16).
    View in: PubMed
    Score: 0.050
  2. Bristow MR. Treatment of chronic heart failure with ?-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011 Oct 28; 109(10):1176-94.
    View in: PubMed
    Score: 0.022
  3. Port JD, Bristow MR. Aptamer therapy for heart failure? Circ Res. 2011 Oct 14; 109(9):982-3.
    View in: PubMed
    Score: 0.022
  4. Sucharov CC, Dockstader K, Nunley K, McKinsey TA, Bristow M. ?-Adrenergic receptor stimulation and activation of protein kinase A protect against a1-adrenergic-mediated phosphorylation of protein kinase D and histone deacetylase 5. J Card Fail. 2011 Jul; 17(7):592-600.
    View in: PubMed
    Score: 0.021
  5. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006 Jul 25; 103(30):11288-93.
    View in: PubMed
    Score: 0.015
  6. Sucharov CC, Mariner PD, Nunley KR, Long C, Leinwand L, Bristow MR. A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am J Physiol Heart Circ Physiol. 2006 Sep; 291(3):H1299-308.
    View in: PubMed
    Score: 0.015
  7. Movsesian MA, Bristow MR. Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy. Curr Top Dev Biol. 2005; 68:25-48.
    View in: PubMed
    Score: 0.014
  8. Rubino M, Travers JG, Headrick AL, Enyart BT, Lemieux ME, Cavasin MA, Schwisow JA, Hardy EJ, Kaltenbacher KJ, Felisbino MB, Jonas E, Ambardekar AV, Bristow MR, Koch KA, McKinsey TA. Inhibition of Eicosanoid Degradation Mitigates Fibrosis of the Heart. Circ Res. 2023 01 06; 132(1):10-29.
    View in: PubMed
    Score: 0.012
  9. Bristow MR, Long CS. Cardiotrophin-1 in heart failure. Circulation. 2002 Sep 17; 106(12):1430-2.
    View in: PubMed
    Score: 0.012
  10. Zhao Y, Riching AS, Knight WE, Chi C, Broadwell LJ, Du Y, Abdel-Hafiz M, Ambardekar AV, Irwin DC, Proenza C, Xu H, Leinwand LA, Walker LA, Woulfe KC, Bristow MR, Buttrick PM, Song K. Cardiomyocyte-Specific Long Noncoding RNA Regulates Alternative Splicing of the Triadin Gene in the Heart. Circulation. 2022 08 30; 146(9):699-714.
    View in: PubMed
    Score: 0.012
  11. Li H, Trager LE, Liu X, Hastings MH, Xiao C, Guerra J, To S, Li G, Yeri A, Rodosthenous R, Silverman MG, Das S, Ambardekar AV, Bristow MR, Gonz?lez-Rosa JM, Rosenzweig A. lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth. Circulation. 2022 04 19; 145(16):1218-1233.
    View in: PubMed
    Score: 0.011
  12. Port JD, Bristow MR. beta-Adrenergic receptors, transgenic mice, and pharmacological model systems. Mol Pharmacol. 2001 Oct; 60(4):629-31.
    View in: PubMed
    Score: 0.011
  13. Woulfe KC, Jeffrey DA, Pires Da Silva J, Wilson CE, Mahaffey JH, Lau E, Slavov D, Hailu F, Karimpour-Fard A, Dockstader K, Bristow MR, Stauffer BL, Miyamoto SD, Sucharov CC. Serum response factor deletion 5 regulates phospholamban phosphorylation and calcium uptake. J Mol Cell Cardiol. 2021 10; 159:28-37.
    View in: PubMed
    Score: 0.011
  14. Shakar SF, Bristow MR. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents. Curr Cardiol Rep. 2001 May; 3(3):224-31.
    View in: PubMed
    Score: 0.011
  15. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001 May; 33(5):887-905.
    View in: PubMed
    Score: 0.011
  16. Bristow M. Of phospholamban, mice, and humans with heart failure. Circulation. 2001 Feb 13; 103(6):787-8.
    View in: PubMed
    Score: 0.011
  17. Bristow M. Etomoxir: a new approach to treatment of chronic heart failure. Lancet. 2000 Nov 11; 356(9242):1621-2.
    View in: PubMed
    Score: 0.010
  18. Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori A, Bristow MR. Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Am J Physiol. 1999 05; 276(5):H1678-90.
    View in: PubMed
    Score: 0.009
  19. Gerdes AM, Onodera T, Tamura T, Said S, Bohlmeyer TJ, Abraham WT, Bristow MR. New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. J Card Fail. 1998 Dec; 4(4):343-8.
    View in: PubMed
    Score: 0.009
  20. Myers VD, Gerhard GS, McNamara DM, Tomar D, Madesh M, Kaniper S, Ramsey FV, Fisher SG, Ingersoll RG, Kasch-Semenza L, Wang J, Hanley-Yanez K, Lemster B, Schwisow JA, Ambardekar AV, Degann SH, Bristow MR, Sheppard R, Alexis JD, Tilley DG, Kontos CD, McClung JM, Taylor AL, Yancy CW, Khalili K, Seidman JG, Seidman CE, McTiernan CF, Cheung JY, Feldman AM. Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals. JAMA Cardiol. 2018 10 01; 3(10):929-938.
    View in: PubMed
    Score: 0.009
  21. Bristow MR, Zisman LS, Lowes BD, Abraham WT, Badesch DB, Groves BM, Voelkel NF, Lynch DM, Quaife RA. The pressure-overloaded right ventricle in pulmonary hypertension. Chest. 1998 Jul; 114(1 Suppl):101S-106S.
    View in: PubMed
    Score: 0.009
  22. Bristow MR. Tumor necrosis factor-alpha and cardiomyopathy. Circulation. 1998 Apr 14; 97(14):1340-1.
    View in: PubMed
    Score: 0.009
  23. Bristow M, Port JD. Beta-adrenergic blockade in chronic heart failure. Scand Cardiovasc J Suppl. 1998; 47:45-55.
    View in: PubMed
    Score: 0.008
  24. Bristow MR, Abraham WT. Anti-adrenergic effects of angiotensin converting enzyme inhibitors. Eur Heart J. 1995 Nov; 16 Suppl K:37-41.
    View in: PubMed
    Score: 0.007
  25. Deisher TA, Ginsburg R, Fowler MB, Billingham ME, Bristow MR. Spontaneous reversibility of catecholamine-induced cardiotoxicity in rats. Am J Cardiovasc Pathol. 1995; 5(1):79-88.
    View in: PubMed
    Score: 0.007
  26. Le CH, Mulligan CM, Routh MA, Bouma GJ, Frye MA, Jeckel KM, Sparagna GC, Lynch JM, Moore RL, McCune SA, Bristow M, Zarini S, Murphy RC, Chicco AJ. Delta-6-desaturase links polyunsaturated fatty acid metabolism with phospholipid remodeling and disease progression in heart failure. Circ Heart Fail. 2014 Jan; 7(1):172-83.
    View in: PubMed
    Score: 0.006
  27. Port JD, Debellis CC, Klein J, Peeters GA, Barry WH, Bristow MR. Pharmacological characterization of chick and frog beta adrenergic receptors in primary cultures of myocardial cells. J Pharmacol Exp Ther. 1992 Jul; 262(1):217-24.
    View in: PubMed
    Score: 0.006
  28. Dockstader K, Nunley K, Karimpour-Fard A, Medway A, Nelson P, Port JD, Liggett SB, Bristow MR, Sucharov CC. Temporal analysis of mRNA and miRNA expression in transgenic mice overexpressing Arg- and Gly389 polymorphic variants of the ?1-adrenergic receptor. Physiol Genomics. 2011 Dec 05; 43(23):1294-306.
    View in: PubMed
    Score: 0.005
  29. Hershberger RE, Feldman AM, Anderson FL, Kimball JA, Wynn JR, Bristow MR. Mr 40,000 and Mr 39,000 pertussis toxin substrates are increased in surgically denervated dog ventricular myocardium. J Cardiovasc Pharmacol. 1991 Apr; 17(4):568-75.
    View in: PubMed
    Score: 0.005
  30. O'Connell JB, Renlund DG, Hammond EH, Wittwer CT, Yowell RL, DeWitt CW, Jones KW, Gay WA, Menlove RL, Bristow MR. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss. J Heart Lung Transplant. 1991 Mar-Apr; 10(2):217-21; discussion 221-2.
    View in: PubMed
    Score: 0.005
  31. Feiner EC, Chung P, Jasmin JF, Zhang J, Whitaker-Menezes D, Myers V, Song J, Feldman EW, Funakoshi H, Degeorge BR, Yelamarty RV, Koch WJ, Lisanti MP, McTiernan CF, Cheung JY, Bristow MR, Chan TO, Feldman AM. Left ventricular dysfunction in murine models of heart failure and in failing human heart is associated with a selective decrease in the expression of caveolin-3. J Card Fail. 2011 Mar; 17(3):253-63.
    View in: PubMed
    Score: 0.005
  32. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990 Aug; 82(2 Suppl):I12-25.
    View in: PubMed
    Score: 0.005
  33. Feldman AM, Bristow MR. The beta-adrenergic pathway in the failing human heart: implications for inotropic therapy. Cardiology. 1990; 77 Suppl 1:1-32.
    View in: PubMed
    Score: 0.005
  34. Shaddy RE, Mak C, Bristow MR. Comparative in vitro myocardial inotropic effects and in vivo hemodynamic effects of forskolin and isoproterenol in young lambs. Pediatr Res. 1989 Jun; 25(6):580-4.
    View in: PubMed
    Score: 0.005
  35. Carnegie GK, Soughayer J, Smith FD, Pedroja BS, Zhang F, Diviani D, Bristow MR, Kunkel MT, Newton AC, Langeberg LK, Scott JD. AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway. Mol Cell. 2008 Oct 24; 32(2):169-79.
    View in: PubMed
    Score: 0.004
  36. Anderson FL, Kralios AC, Hershberger R, Bristow MR. Effect of vasoactive intestinal peptide on myocardial contractility and coronary blood flow in the dog: comparison with isoproterenol and forskolin. J Cardiovasc Pharmacol. 1988 Sep; 12(3):365-71.
    View in: PubMed
    Score: 0.004
  37. Anderson FL, Kralios AC, Hershberger R, Bristow MR. Desensitization of myocardial but not coronary VIP receptor-mediated responses in dogs. Am J Physiol. 1988 Sep; 255(3 Pt 2):H601-7.
    View in: PubMed
    Score: 0.004
  38. Bristow MR, Sandoval AB, Gilbert EM, Deisher T, Minobe W, Rasmussen R. Myocardial alpha- and beta-adrenergic receptors in heart failure: is cardiac-derived norepinephrine the regulatory signal? Eur Heart J. 1988 Jun; 9 Suppl H:35-40.
    View in: PubMed
    Score: 0.004
  39. Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol. 2008 Aug; 45(2):185-92.
    View in: PubMed
    Score: 0.004
  40. Sparagna GC, Chicco AJ, Murphy RC, Bristow MR, Johnson CA, Rees ML, Maxey ML, McCune SA, Moore RL. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J Lipid Res. 2007 Jul; 48(7):1559-70.
    View in: PubMed
    Score: 0.004
  41. Taylor MR, Slavov D, Ku L, Di Lenarda A, Sinagra G, Carniel E, Haubold K, Boucek MM, Ferguson D, Graw SL, Zhu X, Cavanaugh J, Sucharov CC, Long CS, Bristow MR, Lavori P, Mestroni L. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation. 2007 Mar 13; 115(10):1244-51.
    View in: PubMed
    Score: 0.004
  42. Bush EW, Hood DB, Papst PJ, Chapo JA, Minobe W, Bristow MR, Olson EN, McKinsey TA. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J Biol Chem. 2006 Nov 03; 281(44):33487-96.
    View in: PubMed
    Score: 0.004
  43. Sucharov CC, Langer S, Bristow M, Leinwand L. Shuttling of HDAC5 in H9C2 cells regulates YY1 function through CaMKIV/PKD and PP2A. Am J Physiol Cell Physiol. 2006 Nov; 291(5):C1029-37.
    View in: PubMed
    Score: 0.004
  44. Xu Y, Lu L, Greyson C, Rizeq M, Nunley K, Wyatt B, Bristow MR, Long CS, Schwartz GG. The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2006 May; 290(5):H1798-807.
    View in: PubMed
    Score: 0.004
  45. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985 Jul; 17 Suppl 2:41-52.
    View in: PubMed
    Score: 0.004
  46. Kinugawa K, Jeong MY, Bristow MR, Long CS. Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase. Mol Endocrinol. 2005 Jun; 19(6):1618-28.
    View in: PubMed
    Score: 0.004
  47. Kantrowitz NE, Bristow MR. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis. 1984 Nov-Dec; 27(3):195-200.
    View in: PubMed
    Score: 0.003
  48. Bristow MR, Ginsburg R, Strosberg A, Montgomery W, Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest. 1984 Jul; 74(1):212-23.
    View in: PubMed
    Score: 0.003
  49. Bristow MR, Ginsburg R, Laser JA, McAuley BJ, Minobe W. Tissue response selectivity of calcium antagonists is not due to heterogeneity of [3H]-nitrendipine binding sites. Br J Pharmacol. 1984 Jun; 82(2):309-20.
    View in: PubMed
    Score: 0.003
  50. Bristow MR, Kantrowitz NE, Harrison WD, Minobe WA, Sageman WS, Billingham ME. Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharmacol. 1983 Nov-Dec; 5(6):913-9.
    View in: PubMed
    Score: 0.003
  51. Sucharov CC, Mariner P, Long C, Bristow M, Leinwand L. Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter. J Biol Chem. 2003 Aug 15; 278(33):31233-9.
    View in: PubMed
    Score: 0.003
  52. Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sageman WS, Daniels JR. Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab Invest. 1981 Aug; 45(2):157-68.
    View in: PubMed
    Score: 0.003
  53. Freeman K, Lerman I, Kranias EG, Bohlmeyer T, Bristow MR, Lefkowitz RJ, Iaccarino G, Koch WJ, Leinwand LA. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 2001 Apr; 107(8):967-74.
    View in: PubMed
    Score: 0.003
  54. Sinagra G, Di Lenarda A, Brodsky GL, Taylor MR, Muntoni F, Pinamonti B, Carniel E, Driussi M, Bristow MR, Mestroni L. Current perspective new insights into the molecular basis of familial dilated cardiomyopathy. Ital Heart J. 2001 Apr; 2(4):280-6.
    View in: PubMed
    Score: 0.003
  55. Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, Snidow GH, Daniels JR. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol. 1980 Sep-Oct; 2(5):487-515.
    View in: PubMed
    Score: 0.003
  56. Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A, Roden R, Asano K, Blaxall BC, Wu SC, Communal C, Singh K, Colucci W, Bristow MR, Port DJ. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000 May; 32(5):817-30.
    View in: PubMed
    Score: 0.002
  57. Bristow MR, Schwartz HD, Binetti G, Harrison DC, Daniels JR. Ionized calcium and the heart. Elucidation of in vivo concentration-response relationships in the open-chest dog. Circ Res. 1977 Oct; 41(4):565-74.
    View in: PubMed
    Score: 0.002
  58. Bristow MR, Daniels JR, Kernoff RS, Harrison DC. Effect of D600, practolol, and alterations in magnesium on ionized calcium concentration-response relationships in the intact dog heart. Circ Res. 1977 Oct; 41(4):574-81.
    View in: PubMed
    Score: 0.002
  59. Cohn JN, Bristow MR, Chien KR, Colucci WS, Frazier OH, Leinwand LA, Lorell BH, Moss AJ, Sonnenblick EH, Walsh RA, Mockrin SC, Reinlib L. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation. 1997 Feb 18; 95(4):766-70.
    View in: PubMed
    Score: 0.002
  60. Ma H, Hammond EH, Taylor DO, Yowell RL, Bristow MR, O'Connell JB, Renlund DG. The repetitive histologic pattern of vascular cardiac allograft rejection. Increased incidence associated with longer exposure to prophylactic murine monoclonal anti-CD3 antibody (OKT3). Transplantation. 1996 Jul 27; 62(2):205-10.
    View in: PubMed
    Score: 0.002
  61. Abraham WT, Raynolds MV, Gottschall B, Badesch DB, Wynne KM, Groves BM, Lowes BD, Bristow MR, Perryman MB, Voelkel NF. Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology. 1995; 86 Suppl 1:9-15.
    View in: PubMed
    Score: 0.002
  62. Green RD, Lefever GS, Sheys EM, Bristow M. On the specificity of alpha adrenergic receptor labeling by 14C-dibenamine. J Pharmacol Exp Ther. 1973 Dec; 187(3):524-8.
    View in: PubMed
    Score: 0.002
  63. Deisher TA, Narita H, Zera P, Ginsburg R, Bristow MR, Billingham ME, Fowler MB, Hoffman BB. Protective effect of clentiazem against epinephrine-induced cardiac injury in rats. J Pharmacol Exp Ther. 1993 Jul; 266(1):262-9.
    View in: PubMed
    Score: 0.002
  64. O'Connell JB, Bristow MR, Hammond EH, Menlove RL, Ensley RD, Ratkovec RM, Renlund DG. Antimurine antibody to OKT3 in cardiac transplantation: implications for prophylaxis and retreatment of rejection. Transplant Proc. 1991 Feb; 23(1 Pt 2):1157-9.
    View in: PubMed
    Score: 0.001
  65. Bristow M, Green RD. A quantitative study of beta-adrenergic receptors in rabbit atria. Eur J Pharmacol. 1970 Sep 01; 12(1):120-3.
    View in: PubMed
    Score: 0.001
  66. Kantrowitz NE, Ellis AK, Bristow MR, Minobe W, Billingham ME, Harrison DC. Histamine mediates myocardial damage by an H1 mechanism independent of coronary blood flow. J Cardiovasc Pharmacol. 1990 Jan; 15(1):82-8.
    View in: PubMed
    Score: 0.001
  67. Bristow M, Sherrod TR, Green RD. Analysis of beta receptor drug interactions in isolated rabbit atrium, aorta, stomach and trachea. J Pharmacol Exp Ther. 1970 Jan; 171(1):52-61.
    View in: PubMed
    Score: 0.001
  68. Wittwer CT, Bristow MR, Gilbert EM, Renlund DG, O'Connell JB, DeWitt CW. OKT3 therapy as a cause of high panel-reactive antibodies in serum using standard microcytotoxicity techniques. Transplantation. 1988 Apr; 45(4):832-4.
    View in: PubMed
    Score: 0.001
  69. Lurie KG, Bristow MR, Minobe WA, Masek M, Billingham ME. 6-Hydroxydopamine mediated cardiotoxicity in rabbits. Am J Cardiovasc Pathol. 1988; 2(2):181-91.
    View in: PubMed
    Score: 0.001
  70. Tsujimoto G, Bristow MR, Hoffman BB. Identification of alpha 1 adrenergic receptors in rabbit aorta with [125I] BE2254. Life Sci. 1984 Feb 13; 34(7):639-46.
    View in: PubMed
    Score: 0.001
  71. Lurie KG, Bristow MR, Reitz BA. Increased beta-adrenergic receptor density in an experimental model of cardiac transplantation. J Thorac Cardiovasc Surg. 1983 Aug; 86(2):195-201.
    View in: PubMed
    Score: 0.001
  72. Kantrowitz NE, Bristow MR, Minobe WA, Billingham ME, Harrison DC. Histamine-mediated myocardial damage in rabbits. J Mol Cell Cardiol. 1982 Sep; 14(9):551-5.
    View in: PubMed
    Score: 0.001
  73. Lurie KG, Billingham ME, Masek MA, Ginsburg R, Bristow MR, Harrison D, Reitz BA. Ultrastructural and functional studies on prolonged myocardial preservation in an experimental heart transplant model. J Thorac Cardiovasc Surg. 1982 Jul; 84(1):122-9.
    View in: PubMed
    Score: 0.001
  74. Clusin WT, Bristow MR, Baim DS, Schroeder JS, Jaillon P, Brett P, Harrison DC. The effects of diltiazem and reduced serum ionized calcium on ischemic ventricular fibrillation in the dog. Circ Res. 1982 Apr; 50(4):518-26.
    View in: PubMed
    Score: 0.001
  75. Clusin WT, Bristow MR, Karagueuzian HS, Katzung BG, Schroeder JS. Do calcium-dependent ionic currents mediate ischemic ventricular fibrillation? Am J Cardiol. 1982 Feb 18; 49(3):606-12.
    View in: PubMed
    Score: 0.001
  76. Ginsburg R, Bristow MR, Harrison DC, Stinson EB. Studies with isolated human coronary arteries. Some general observations, potential mediators of spasm, role of calcium antagonists. Chest. 1980 Jul; 78(1 Suppl):180-6.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)